The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction

Figures & data

Table 1 The most common adverse events (AEs) reported for tadalafil in the different studies included in this review, n (%). Overall number of events for each drug and for each single AE are reported (%).

AE	Arm	McVary et al, ^Citation44 2007	Roehrborn et al,^Citation45 2008				Porst et al,^Citation48 2009				Dmochowski et al,^Citation50 2010	Porst et al,^Citation51 2011	Donatucci et al,^Citation52 2011	Oelke et al,^Citation53 2012	Yokoyama et al,^Citation55 2012	Overall
	Dose	10 mg	2.5 mg	5 mg	10 mg	20 mg	2.5 mg	5 mg	10 mg	20 mg	20 mg	5 mg	5 mg	5 mg	5 mg
Headache	D	4 (2.9)	5 (2.4)	6 (2.8)	11 (5.1)	7 (3.3)	4 (3.5)	4 (3.4)	6 (5.0)	2 (1.7)	3 (3.0)	6 (3.7)	0	5 (2.9)	3 (1.9)	66 (11.1)
	P	1 (0.7)	6 (2.8)				4 (3.5)				7 (7.1)	1(0.6)	3 (3.3)	2 (1.2)	1 (0.6)	25 (11.2)
Dyspepsia	D	6 (4.3)	2 (1.0)	10 (4.7)	6 (2.8)	10 (4.8)	1 (0.9)	5 (4.3)	2 (1.7)	3 (2.6)	8 (8.1)		4 (4.8)	4 (2.3)		61 (10.2)
	P	0	0				0				0		4(4.3)	0		4 (1.8)
Back pain	D	5 (3.6)	3 (1.4)	2 (0.9)	10 (4.6)	12 (5.7)	2 (1.8)	1 (0.9)	5 (4.2)	6 (5.2)	5 (5.1)	5 (3.1)	2 (2.4)	4 (2.3)	4 (2.6)	66 (11.1)
	P	2 (1.4)	1 (0.5)				1 (0.9)				3 (3.0)	4 (2.4)	4 (4.3)	1 (0.6)	1 (0.6)	17 (7.6)
G.E.Reflux	D		2 (1.0)	2 (0.9)	6 (2.8)	3 (1.4)					3 (3.0)		2 (2.4)			18 (3.0)
	P		0								0		2(2.2)			2 (0.9)
Sinusitis	D												2 (2.4)			2 (0.3)
	P												0			0
Rhinitis	D	3 (2.2)	7 (3.3)	4 (1.9)	2 (0.9)	5 (2.4)								5 (2.9)	2 (1.3)	2 (0.3)
	P	0	2 (0.9)											8 (4.7)	4 (2.6)	14 (6.3)
Hypertension	D												3 (3.6)			3 (0.5)
	P												0			0
Myalgia	D		3 (1.4)	3 (1.4)	6 (2.8)	6 (2.9)	2 (1.8)	1 (0.9)	4 (3.3)	3 (2.6)					6 (3.9)	34 (5.7)
	P		0				0								0	0
Cough	D												1 (1.2)			1 (0.2)
	P												1 (1.1)			1 (0.5)
Other	D	16 (11.2)	14	16	12	15	24	19	25	29	36	31	33	22	32	318 (53.2)
	P	3 (2.1)	5				19				18	31	36	24	24	160 (71.7)
Overall	D	28	36	43	53	58	33 (29.2)	30 (25.6)	42 (35.0)	43 (37.1)	55 (55.6)	42 (26.1)	47 (56.6)	40 (23.4)	47 (30.3)	597
	P	6	14				24 (20.9)				28 (27.7)	36 (22.0)	50 (54.3)	35 (20.3)	30 (19.5)	223

Abbreviations: D, drug; AE, adverse event; GE, gastroesophageal; P, placebo.

Figure 1 Weighted mean differences (with 95% confidence interval) of International Prostate Symptom Score (IPSS) (A) and International Index of Erectile Function-Erectile Function (IIEF-EF) score (B) for the studies on tadalafil versus placebo.

BrigantiANasproRGallinaAImpact on sexual function of holmium laser enucleation versus transurethral resection of the prostate: results of a prospective, 2-center, randomized trialJ Urol200617551817182116600770

 PubMed Web of Science ®Google Scholar

McVaryKTRoehrbornCGKaminetskyJCTadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasiaJ Urol200717741401140717382741

 PubMed Web of Science ®Google Scholar

LiguoriGTrombettaCDe GiorgiGEfficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary reportJ Sex Med20096254455219138360

 PubMed Web of Science ®Google Scholar

RoehrbornCGKaminetskyJCAuerbachSMMontelongoRMElion-MboussaAViktrupLChanges in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatmentBJU Int2010105450250719732051

 PubMed Web of Science ®Google Scholar

DmochowskiRRoehrbornCKliseSXuLKaminetskyJKrausSUrodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trialJ Urol201018331092109720092847

 PubMed Web of Science ®Google Scholar

PorstHKimEDCasabéARLVHJ study teamEfficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trialEur Urol20116051105111321871706

 PubMed Web of Science ®Google Scholar

DonatucciCFBrockGBGoldfischerERTadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension studyBJU Int201110771110111621244606

 PubMed Web of Science ®Google Scholar

RegadasRPRegesRCerqueiraJBUrodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trialInt Urol Nephrol2012451394323108604

 PubMed Web of Science ®Google Scholar